AI Engines For more Details: Perplexity Kagi Labs You
Fungal Skin Infections: Clotrimazole is commonly used to treat fungal skin infections such as athlete's foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). It works by inhibiting the growth and multiplication of fungal organisms responsible for these infections, thereby relieving symptoms such as itching, redness, scaling, and discomfort. Clotrimazole is available in various formulations, including creams, lotions, sprays, and powders, for topical application to the affected skin areas.
Yeast Infections: Clotrimazole is also used to treat yeast infections, particularly vaginal yeast infections (vulvovaginal candidiasis) caused by Candida species. It is available in vaginal cream or suppository formulations for intravaginal use. Clotrimazole helps eliminate yeast overgrowth and restore the natural balance of microorganisms in the vaginal flora, thereby relieving symptoms such as vaginal itching, burning, discharge, and discomfort.
Oral Thrush: Clotrimazole may be used to treat oral thrush (oral candidiasis), a fungal infection of the mouth and throat caused by Candida species. It is available in oral troche (lozenge) or oral suspension formulations for local application to the affected oral mucosa. Clotrimazole helps reduce the growth of yeast in the mouth, throat, and esophagus, thereby alleviating symptoms such as white patches or plaques, soreness, and difficulty swallowing.
Nail Fungus: Clotrimazole is sometimes used off-label in the treatment of nail fungus (onychomycosis), although it is less commonly prescribed for this indication compared to other antifungal medications. It may be used in combination with other antifungal agents or as part of topical therapy for superficial nail infections caused by dermatophyte fungi. However, oral antifungal medications are generally preferred for the treatment of more severe or resistant cases of nail fungus.
Dosage and Administration: The dosage and duration of clotrimazole therapy depend on the specific fungal infection being treated, the severity of symptoms, and the individual patient's response to treatment. Clotrimazole formulations are applied topically to the affected skin areas, vaginal mucosa, oral mucosa, or nails as directed by the healthcare provider. Treatment may range from a few days to several weeks, depending on the type and location of the infection.
Side Effects: Common side effects of clotrimazole may include mild skin irritation, itching, burning, or redness at the site of application. These side effects are usually transient and resolve with continued use or upon discontinuation of the medication. Allergic reactions to clotrimazole are rare but may manifest as severe skin irritation, rash, or swelling. Patients should discontinue use and seek medical attention if they experience signs of an allergic reaction.
Contraindications and Precautions: Clotrimazole is generally well-tolerated and safe for most individuals when used as directed. It is contraindicated in individuals with known hypersensitivity to clotrimazole or any of its components. Clotrimazole should be used with caution in patients with open wounds, mucosal ulcerations, or known immune deficiencies. It is for external use only and should be kept away from eyes, nose, mouth, and other mucous membranes to avoid irritation or adverse effects.
Rank | Probiotic | Impact |
---|---|---|
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
Acne | 0.5 | -0.5 | |
ADHD | 6.9 | 1 | 5.9 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
Allergic Rhinitis (Hay Fever) | 2.7 | 2.5 | 0.08 |
Allergies | 6.8 | 3.5 | 0.94 |
Allergy to milk products | 1.9 | 1.2 | 0.58 |
Alopecia (Hair Loss) | 2.5 | 2.5 | |
Alzheimer's disease | 4.1 | 9.4 | -1.29 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.2 | 0.9 | 3.67 |
Ankylosing spondylitis | 5.4 | 2.5 | 1.16 |
Anorexia Nervosa | 0.5 | 3.5 | -6 |
Antiphospholipid syndrome (APS) | 2.9 | 0.3 | 8.67 |
Asthma | 1.9 | 1 | 0.9 |
Atherosclerosis | 1.5 | 2.9 | -0.93 |
Atrial fibrillation | 5.2 | 3 | 0.73 |
Autism | 13.7 | 13.2 | 0.04 |
Barrett esophagus cancer | 0.3 | 0.4 | -0.33 |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 2 | 2.3 | -0.15 |
Brain Trauma | 1 | 1 | 0 |
Carcinoma | 5.3 | 3.9 | 0.36 |
Celiac Disease | 3.1 | 5.5 | -0.77 |
Cerebral Palsy | 1.7 | 2 | -0.18 |
Chronic Fatigue Syndrome | 8.6 | 9.6 | -0.12 |
Chronic Kidney Disease | 3.7 | 3 | 0.23 |
Chronic Lyme | 1 | -1 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2.4 | 1.5 | 0.6 |
Chronic Urticaria (Hives) | 1.9 | 2 | -0.05 |
Coagulation / Micro clot triggering bacteria | 1.6 | 1.9 | -0.19 |
Colorectal Cancer | 5.6 | 1.5 | 2.73 |
Constipation | 2.2 | 1 | 1.2 |
Coronary artery disease | 2.5 | 1.3 | 0.92 |
COVID-19 | 16.2 | 21.2 | -0.31 |
Crohn's Disease | 10.2 | 8.5 | 0.2 |
cystic fibrosis | 0.7 | 1.5 | -1.14 |
deep vein thrombosis | 0.7 | 1.4 | -1 |
Depression | 14.7 | 11.9 | 0.24 |
Dermatomyositis | 0.4 | 0.5 | -0.25 |
Eczema | 1.5 | 3.4 | -1.27 |
Endometriosis | 4.1 | 1.8 | 1.28 |
Eosinophilic Esophagitis | 0 | 0.3 | 0 |
Epilepsy | 3.6 | 3 | 0.2 |
Fibromyalgia | 4.5 | 4.5 | 0 |
Functional constipation / chronic idiopathic constipation | 8.6 | 6.5 | 0.32 |
gallstone disease (gsd) | 3 | 1 | 2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.3 | 1.4 | 0.64 |
Generalized anxiety disorder | 2.2 | 3 | -0.36 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.4 | -0.4 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 2 | 2 | 0 |
Halitosis | 0.8 | 0.4 | 1 |
Hashimoto's thyroiditis | 3.5 | 1.3 | 1.69 |
Hidradenitis Suppurativa | 0.7 | 0.3 | 1.33 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 4.9 | 1.5 | 2.27 |
hypercholesterolemia (High Cholesterol) | 0.9 | 0.9 | |
hyperglycemia | 0.2 | 2 | -9 |
Hyperlipidemia (High Blood Fats) | 1 | 0.5 | 1 |
hypersomnia | 0.8 | -0.8 | |
hypertension (High Blood Pressure | 3.1 | 7.1 | -1.29 |
Hypothyroidism | 2 | -2 | |
Hypoxia | 1 | 1 | |
IgA nephropathy (IgAN) | 7 | -7 | |
Inflammatory Bowel Disease | 7 | 12.5 | -0.79 |
Insomnia | 1.4 | 1.5 | -0.07 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 2 | 0.5 | 3 |
Irritable Bowel Syndrome | 5.5 | 5.8 | -0.05 |
Liver Cirrhosis | 6.2 | 4.5 | 0.38 |
Long COVID | 12.4 | 13.2 | -0.06 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 1.2 | 1.5 | -0.25 |
ME/CFS with IBS | 1.9 | 4 | -1.11 |
ME/CFS without IBS | 3.3 | 3.5 | -0.06 |
Menopause | 3 | 3 | |
Metabolic Syndrome | 11.3 | 12 | -0.06 |
Mood Disorders | 18.1 | 12.3 | 0.47 |
multiple chemical sensitivity [MCS] | 1.7 | 0.5 | 2.4 |
Multiple Sclerosis | 7.3 | 8.9 | -0.22 |
Multiple system atrophy (MSA) | 1.7 | 1.5 | 0.13 |
Neuropathy (all types) | 0.9 | 0.2 | 3.5 |
neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.6 | 7.4 | -1.06 |
NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
Obesity | 12.8 | 6.4 | 1 |
obsessive-compulsive disorder | 9.7 | 6.4 | 0.52 |
Osteoarthritis | 3.6 | 0.5 | 6.2 |
Osteoporosis | 2.5 | 1 | 1.5 |
pancreatic cancer | 0.9 | 0.9 | |
Parkinson's Disease | 3.6 | 6 | -0.67 |
Polycystic ovary syndrome | 3.7 | 2.9 | 0.28 |
Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
Premenstrual dysphoric disorder | 1.5 | 0.5 | 2 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 6.2 | 4 | 0.55 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.4 | 5.3 | 0.77 |
Rosacea | 2 | 1 | 1 |
Schizophrenia | 9.8 | 3 | 2.27 |
scoliosis | 0.5 | 1.8 | -2.6 |
Sjögren syndrome | 4 | 5 | -0.25 |
Sleep Apnea | 2 | 2.5 | -0.25 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.9 | 1 | -0.11 |
Stress / posttraumatic stress disorder | 3.5 | 3.4 | 0.03 |
Systemic Lupus Erythematosus | 6.2 | 2.9 | 1.14 |
Tic Disorder | 1.9 | 2.6 | -0.37 |
Tourette syndrome | 0.5 | -0.5 | |
Type 1 Diabetes | 5.8 | 3.9 | 0.49 |
Type 2 Diabetes | 11.8 | 9.7 | 0.22 |
Ulcerative colitis | 4 | 7.7 | -0.93 |
Unhealthy Ageing | 8.4 | 2.9 | 1.9 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.